Cataract surgery is the most commonly performed surgery in the United States. Despite this, we know surprisingly little about visual outcomes and rates of complications following contemporary cataract surgery, especially in population subgroups. This lack of knowledge is troubling given that emerging research from Europe suggests that cataract surgery might be ineffective for up to 6% of patients and present significant harms to another 2- 5%. Cystoid macular edema (CME), for example, is a common postoperative complication of cataract surgery. Since the adoption of optical coherence tomography, CME incidence has risen from ~2% to ~40%. However, cataract surgeons lack a clear understanding of what this diagnosis means. To address this issue, we propose a cohort study to generate real-world knowledge about cataract surgery prognosis, including visual outcomes and complication rates; CME diagnostic criteria that correlate with late postoperative vision loss; the prevention of significant CME; and differences in these topics among vulnerable population subgroups. The proposed study will include comprehensive, prospectively recorded data for approximately 186,000 patients and more than 250,000 eyes that received surgery at Kaiser Permanente Northern California from 2007 to 2016. The study will be the largest in the U.S.; will use detailed, comprehensive information that is prospectively recorded into the electronic medical record; and will use modern analytic techniques to ensure valid analyses. The well- characterized, community-based population is diverse, with 29% of patients being non-white and 43% having an ocular comorbidity. Together with the large number of cases, this high level of diversity will enable detailed sensitivity and subgroup analysis. Our results will allow cataract surgeons to individualize care for their patients. The results will also provide desperately needed evidence-based diagnostic criteria for CME. These criteria can be used in research studies, in clinical practice, and to develop practice guidelines. The exceptional volume of cataract surgery justifies research to improve decision-making of this life-changing surgery.

Public Health Relevance

Cataract surgery is the most common surgery performed in the U.S., and its effectiveness and safety are highly significant. The proposed study will allow surgeons to tailor the prognosis (projected final visual acuity and risk of complications), to the individual patient based on their ocular comorbidities. It will also help ophthalmologists understand the importance of quantitative measures of post-operative macular edema seen on optical coherence tomography, and it will clarify the benefits and risks of non-steroidal anti- inflammatory drugs used to prevent macular edema.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
1R01EY027329-01
Application #
9215348
Study Section
Special Emphasis Panel (ZEY1-VSN (02))
Program Officer
Bhargava, Sangeeta
Project Start
2017-03-01
Project End
2019-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
1
Fiscal Year
2017
Total Cost
$369,619
Indirect Cost
$133,155
Name
Kaiser Foundation Research Institute
Department
Type
Research Institutes
DUNS #
150829349
City
Oakland
State
CA
Country
United States
Zip Code
94612
Herrinton, Lisa J; Liu, Liyan; Alexeeff, Stacey et al. (2017) Immediate Sequential vs. Delayed Sequential Bilateral Cataract Surgery: Retrospective Comparison of Postoperative Visual Outcomes. Ophthalmology 124:1126-1135
Naseri, Ayman; Melles, Ronald B; Shorstein, Neal H (2017) Intracameral Antibiotics in the Shadow of Hemorrhagic Occlusive Retinal Vasculitis. Ophthalmology 124:580-582
Bulkley, Joanna; McMullen, Carmit K; Hornbrook, Mark C et al. (2013) Spiritual well-being in long-term colorectal cancer survivors with ostomies. Psychooncology 22:2513-21
Asgari, Maryam M; Wu, Jashin J; Gelfand, Joel M et al. (2013) Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. Pharmacoepidemiol Drug Saf 22:842-9